Particle.news
Download on the App Store
3 ARTICLES
·
5d ago

Arvinas’ Vepdegestrant Delays Breast Cancer Progression Longer Than Faslodex

Enrolling 624 previously treated patients at the American Society of Clinical Oncology meeting in Chicago, the trial delivered a more than three-month progression-free survival advantage over Faslodex, prompting Arvinas to cancel two other planned late-stage studies.

Pfizer logo is seen in this illustration taken, May 1, 2022. REUTERS/Dado Ruvic/Illustration
Image

Overview

  • In the overall study population, vepdegestrant achieved a median progression-free survival of 3.8 months compared with 3.6 months for Faslodex.
  • Among patients with ESR1 mutations, the oral PROTAC ER degrader extended progression-free survival by five months versus about two months for injectable Faslodex.
  • Vepdegestrant harnesses the body’s protein disposal system to specifically target and degrade estrogen receptors that drive tumor growth.
  • Arvinas has opted not to proceed with two additional late-stage trials of the drug following the detailed ASCO data.
  • The findings were presented in Chicago at the American Society of Clinical Oncology’s annual meeting and published in The New England Journal of Medicine.